– USA, CA – Viropro, Inc. (OTCBB: VPRO), which has previously announced it will be changing its name to Axxiom, today announced that John Doll has agreed to join its Board of Directors effective immediately.
John Doll retired in October 2009 as Acting Under Secretary of Commerce for Intellectual Property and Acting Director of the United States Patent and Trademark Office (USPTO), where he was responsible for advising the President, the Secretary of Commerce and the Administration about all intellectual property matters. John began his career at USPTO in 1974 as an assistant examiner, and progressed to be Director of Patent Examination responsible for all patent examination issues in the chemistry, chemical engineering, pharmaceutical, biotechnology and design art areas. Before that he was Supervisory Patent Examiner, having examined and supervised the examination of patent applications encompassing pharmaceuticals, herbicides, pesticides, dyestuffs, inorganic chemistry, hydrometallurgy, zeolite catalysts, buckministerfullerenes, proteins, and peptides. “We are delighted and honored to have someone of John’s stature, as a former commissioner of the United States Patent Office, join our Board,” said Dr. Ken Sorensen, Viropro Chairman of the Board. “His decades of experience as a career patent official who rose through the ranks to become the Head of the Office, and his leadership during some of the most formidable changes in the landscape of US and international patent law, will be invaluable to help guide the transformation of Viropro as we continue our efforts to build a world-class company.”
During his time at the USPTO, John won numerous awards for the implementation of the Patent Application Location and Monitoring (PALM) system, the development and implementation of the automated examiner Office Action tools, for establishing the Biotechnology Customer Partnership, and for the implementation of the Image File Wrapper system. “I am excited to join the Board of Viropro as we create a diversified life sciences company focusing on the development of high value therapeutic drugs and services,” Doll said.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
